Press Releases 2025 2024 2023 2022 2021 2020 2019 all June 2, 2021 Dyne Therapeutics Announces Chief Scientific Officer Transition May 26, 2021 Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference May 14, 2021 Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA May 6, 2021 Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights April 27, 2021 New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting March 4, 2021 Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights March 4, 2021 Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer February 8, 2021 Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs January 20, 2021 Dyne Therapeutics Announces Pricing of $168 Million Public Offering January 10, 2021 Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study January 5, 2021 Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference November 9, 2020 Dyne Therapeutics to Present at Upcoming Investor Conferences November 5, 2020 Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights September 21, 2020 Dyne Therapeutics Announces Closing of Initial Public Offering September 16, 2020 Dyne Therapeutics Announces Pricing of Initial Public Offering August 10, 2020 Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases August 3, 2020 Dyne Therapeutics Appoints Susanna High as Chief Operating Officer July 20, 2020 Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board June 11, 2020 Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property May 19, 2020 Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Next page › Last page » Displaying 81 - 100 of 113
